Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03688347 · ClinicalTrials.gov registry record
Microbiome in Lung Cancer and Other Malignancies
A clinical trial of Cancer and Lung Cancer, sponsored by Taher Abu Hejleh.
- Completed
- Registry status
- 44
- Enrollment target
- 1
- Study location
NCT03688347 is a study of Cancer and Lung Cancer that has completed, run by Taher Abu Hejleh. The registered enrollment target is 44 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03688347, a study of Cancer and Lung Cancer, has completed, sponsored by Taher Abu Hejleh.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
To characterize the fecal, skin, nasal and oral microbiome and metabolome in patients with lung cancer and other malignancies, and correlate to treatment response and toxicities of various therapies including immunotherapy, chemotherapy and targeted therapy, etc.
Conditions Studied
Interventions
- PROCEDURE Nasal Swab
- OTHER Stool Collection
- PROCEDURE Oral Swab
- GENETIC Microbiome analysis
- GENETIC DNA Banking
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-08-30 |
| Est. Completion | 2022-05-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03688347
The ClinicalTrials.gov registry entry for NCT03688347 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Taher Abu Hejleh, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Nasal Swab is the first listed.
NCT03688347 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT03688347 about?
NCT03688347 is a clinical study titled "Microbiome in Lung Cancer and Other Malignancies". To characterize the fecal, skin, nasal and oral microbiome and metabolome in patients with lung cancer and other malignancies, and correlate to treatment response and toxicities of various therapies including immunotherapy, chemotherapy and targeted therapy, etc.
What is the current status of trial NCT03688347?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2018-08-30. Estimated completion is 2022-05-09.
What conditions does trial NCT03688347 study?
This clinical trial studies the following conditions: Cancer, Lung Cancer, Malignancy.
What interventions are being tested in trial NCT03688347?
The interventions under investigation include: Nasal Swab (PROCEDURE), Stool Collection (OTHER), Oral Swab (PROCEDURE), Microbiome analysis (GENETIC), DNA Banking (GENETIC).
Who is sponsoring clinical trial NCT03688347?
This trial is sponsored by Taher Abu Hejleh, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03688347 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.